Sacubitril
Entresto, Neparvis (sacubitril) is a small molecule pharmaceutical. Sacubitril was first approved as Entresto on 2015-07-07. It has been approved in Europe to treat heart failure. Entresto's patents are valid until 2036-05-09 (FDA).
| Trade Name | Entresto, Neparvis |
|---|---|
| Common Name | Sacubitril |
| Indication | heart failure |
| Drug Class | Endopeptidase inhibitors |
